
- 3 Chayada Tangshewinsirikul¹, Panyu Panburana¹, Maneerat Prakobpanich², Takol
- 4 Chareonsirisuthigul³, Donniphat Dejsuphong⁴, Thipwimol Tim-aroon⁵, Chaiyos
- 5 Khongkhatithum⁶, Thanyachai Sura⁷, Atchara Tunteeratum⁷, Duangrurdee Wattanasirichaigoon^{5*}
- 6 ¹ Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Faculty of
- 7 Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
- 8 ² Department of Obstetrics and Gynecology, Faculty of Medicine Ramathibodi Hospital, Mahidol
- 9 University, Bangkok, Thailand
- 10 ³ Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University,
- 11 Bangkok, Thailand

1

2

- ⁴ Section for Translational Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol
- 13 University, Bangkok, Thailand
- ⁵ Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine Ramathibodi
- 15 Hospital, Mahidol University, Bangkok, Thailand
- 16 6 Division of Neurology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital,
- 17 Mahidol University, Bangkok, Thailand
- ⁷ Division of Medical Genetics, Department of Internal Medicine, Faculty of Medicine
- 19 Ramathibodi Hospital, Mahidol University, Bangkok, Thailand



ABSTRACT

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

Objectives. To investigate the acceptance rate for spinal muscular atrophy (SMA) carrier screening among Thai pregnant women, their attitudes toward the prenatal screening, carrier rate, and the frequencies of SMN2 copy numbers. Materials and methods. Singleton pregnant women who aged ≥18 years, with a gestational age of <14 weeks at their first visit, were invited to participate the study. All participants completed the questionnaire: Section I - demographic data. Then, they received a pre-test group counseling, followed by an offer of SMA carrier testing at no cost and completion of the questionnaire: Section II - awareness and attitudes toward the screening and Section III – reasons for their choosing 'to have' or 'not to have' the screening done. Only those having the test done and undergoing post-test counseling were asked to complete the questionnaire: Section IV – attitudes toward the screening process. **Results.** We found a high acceptance rate for carrier screening at 91.4% (181/198 participants), a carrier rate of 2.2% (1 in 45), and high frequency of <2 copies of SMN2 (98.3%). The preexisting knowledge about SMA was low (30.8%). The majority of participants became realized about the severity of SMA and its burden to the families (94.4%) and agreed to have fetal diagnosis if they were found to be a couple-at-risk (92.4%). Most participants (98%) suggested that SMA carrier screening should be offered to all pregnant women and that the cost of testing should be covered by the government and/or by their health coverage schemes (95.5%). **Conclusion.** The high acceptance rate and positive attitude toward prenatal SMA carrier was demonstrated among Thai pregnant women. Data from the present study highlight urgent needs

for endorsement from professional society and public health policy in advancing the SMA carrier screening program in Thailand. Key words: spinal muscular atrophy, SMA, prenatal, carrier screening, attitude

Introduction

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

Spinal muscular atrophy (SMA) is a severe neuromuscular disorder which results in progressive muscle weakness, with an estimated incidence of 1 in 6,000-10,000 births worldwide [1]. SMA is divided into four clinical types depending on the age of onset and clinical progression. Type I SMA (Werdnig-Hoffmann) has clinical onset within the first three months of life, usually leading to respiratory failure and death by two years of age. The onset of type II SMA is 6-18 months of age, and the affected children may sit independently but cannot stand or walk, with 70% surviving beyond 25 years of age. Patients with type III SMA (Kugelberg– Welander), with the onset at ≥ 18 months, have difficulty climbing stairs and running and often have a normal lifespan. Type IV SMA or adult-onset SMA is described with slow progression of muscle weakness beginning at around 30 years of age, and with no reduction in life expectancy [2]. Type I SMA has the highest incidence among SMA, at 50-60% [2-5]. However, there is a marked difference between incidence and prevalence of type I SMA because of its low survival [6-7]. Among the living individuals with SMA, types II and III together account for 75-83% [6-9]. Survival motor neuron 1 (SMNI) gene, located on 5q11.2–q13.3, is the disease-causing gene of SMA. Approximately 95-98% of SMA cases are caused by a homozygous deletion of exon 7 or exons 7-8 of the SMN1 gene, with 3%-5% being due to point mutation or compound heterozygosity between the deletion and point mutations [2]. SMN2 is a highly homologous gene of SMN1, they are located next to each other. The complete absence of SMN2 yields no clinical effect on healthy individuals. The copy number of SMN2 rather modifies the severity of SMA [2, 6, 10]. Most people have two copies of SMN1, each on the homologous chromosome, and two copies of SMN2, each on the homologous chromosome as well [2,11], The higher number of

SMN2 copy number is associated with less severity of the SMA phenotypes (1 copy of SMN2: 96% - type I SMA; 2 copies: 79% - type I; 3 copies: 54% - type II and 31% - type III/IV; ≥4 copies: 88% - type III/IV) [2]. Therefore, simultaneous copy number detection of *SMN1*-exon 7 (or exons 7-8) and *SMN2*-exon7 is widely used for molecular diagnosis and prognostication for SMA [2,12]. As for carrier screening in general population, copy number analysis of the *SMN1* is a preferred method, owing to its high throughput, rapid turn-around time, and economical reason [13-15].

Carrier frequency of SMA in general population is high at approximately 1 in 33-94 worldwide [2, 11, 13, 15, 16], and potentially with the most severe phenotype due to the high frequency of ≤2 copies of *SMN2* among the carriers [15, 17-21]. Screening for SMA carrier before conception or early in pregnancy, regardless of religion or ethnicity, has been recommended by the American College of Medical Genetics (2008) and by the American College of Obstetricians and Gynecology (2017) [22, 23].

Thailand is a middle-income country with well-established universal health coverage (UHC) since 2002 (https://eng.nhso.go.th/) Almost all Thai citizens are currently covered by one of the three health benefit schemes: 74% under the Thai UHC, 7% covered by the Civil Servant Medical Benefit Scheme (CSMBS, for government/state employees), and 19% under the Social Security Scheme (SSS for working adults). Notably, 93% of Thai Children are covered by the UHC. Prenatal screening for thalassemia (carrier rate 40%) has been offered as the national policy since 1992, with a good coverage at 98% of pregnant women [24, 25]. Carrier frequency of SMA among Thai population is 1 in 40 [26, 27], but SMA carrier screening is not included in the national program or routine antenatal care in the country. Newborn screening for SMA is not offered and specific treatments for SMA (such as mRNA-modifying treatment and gene therapy)

is not reimbursable under the existing health schemes in the country. Carrier testing for SMA and reproductive choices are offered to only the families with previous affected child/relatives with SMA.

To explore the potentials for establishing carrier screening for SMA during prenatal period, we set off to conduct this study. Our objectives were to assess the acceptance rate of the carrier screening among Thai pregnant women, to evaluate their attitudes toward the screening, to determine the prevalence of SMA carrier and the frequencies of *SMN2* copy numbers.

Materials and Methods

Study design and participants

This was a prospective and descriptive study, conducted during 10 March 2021 and 31 March 2022, at the antenatal care clinic, Ramathibodi Hospital. The protocol was granted by the Ramathibodi Hospital Institutional Review Board (COA, MURA2020/1420) and complied with the Declaration of Helsinki. The study was registered as a clinical trial (registration number NCT04859179).

Eligible participants were women with singleton pregnancy, who were aged ≥ 18 years and capable of reading and understanding Thai, and with a gestational age of ≤ 14 weeks at their first visit with our antenatal care clinic. They were invited to enroll in the study, by one of the authors (MP) and asked to provide a written informed consent. Exclusion criteria were refusal to give a written consent, withdrawal during or after the completion of the study, and insufficient data obtained from the questionnaire.

Questionnaire

A Thai-language questionnaire was developed using information from a literature review, then validated by six clinical experts: two maternal and fetal medicine specialists, two pediatric geneticists, and two clinical scientists. The reliability of the questionnaire was 0.797, as assessed by using Cronbach's alpha.

The questionnaire contained four sections, I-IV. Section I focused on the participants' demographic data, including age, education, occupation, religion, and gravida and previous history of fetal anomalies. Section II asked about awareness and attitudes toward SMA carrier screening. This section comprised of nine question items, including the awareness of severity of SMA and its burden on the patients and families, the usefulness and interest in having prenatal carrier screening for SMA and their confidence in the reliability of the test offered, agreement in having definitive test for fetal diagnosis, possible considering termination of pregnancy as an alternative if the fetus to be found affected, opinion on having SMA carrier screening as part of a standard antenatal care, and their willingness to self-pay for the screening test. The answer options were 'agree', 'not sure', and 'disagree'.

As for Section III, we explored the reason(s) and/or rationale thinking of the participants for choosing 'to have' or 'not to have' the carrier screening test. Multiple choice answers were provided to choose and the participants could choose more than one answer as wanted. We also asked the participants' opinions on a reasonable price for the screening test if it had to be self-pay, and who (individuals, organizations, health schemes, or else), in their opinion, should be responsible for cost of testing if the screening would become part of standard antenatal care in the country.

Section IV consisting five question items, was about the participants' attitudes and reflections of their immediate past experience with going through the SMA carrier screening

process including pre-test and post-test counselling: overall feeling/satisfaction to the screening process, the usefulness of the information provided, the essence of post-test counseling, the whole process is time worthy, and that the carrier screening should be offered to all pregnant women during antenatal visit. The answer options for each question were 'agree', 'not sure', and 'disagree'.

Data collection

All the participants, after the completion of Section I of the questionnaire, were provided with pre-test group counseling delivered by trained maternal and fetal medicine specialists using a PowerPoint presentation which lasted for about 10 minutes. The participants then received the Thai-language brochure to read in a designated area, this was to allow the participants time to digest the information received and self-check of their understanding. The slide presentation for the group counseling and the brochure contained similar information, including the incidence, clinical presentations, natural course and outcomes of SMA; treatment options and the efficacy of available treatments, affordability of the treatment in the country; carrier rate and carrier screening; and prenatal diagnosis and its downstream services.

After pre-test counseling, a free-of-charge SMA carrier testing (as part of this research) was offered to all participants and they were asked to complete the questionnaire Sections II and III, regardless of their choosing to have the test done or not. A sequential prenatal SMA carrier screening protocol was established to use in this research (Figure 1). For those choosing not to have the test done, the study ended at this point. About those choosing to have carrier testing performed, 10-ml of venous blood sample was taken for *SMN1* and *SMN2* analysis.

Post-test counseling for each individual was offered by a maternal and fetal medicine specialist at an antenatal care clinic, upon the result became available. Then, the participants were requested to finalize the Section IV of the questionnaire. For those who were found to be a carrier, their partner was counseled and offered the carrier testing (with no charge). Prenatal diagnosis would be discussed to a couple at risk.

Carrier testing and copy numbers analysis for SMN1 and SMN2

To detect copy number of *SMN1* and *SMN2*, we performed multiple ligation-dependent probe amplification (MLPA) analysis, using a commercially available MLPA kit for SMA (SALSA P021), following the manufacturer's protocol (MRC Holland, Amsterdam, the Netherlands). The MLPA reactions included internal quality controls and negative controls. The PCR products were analyzed using the Applied Biosystems 3500 Genetic Analyzer (Thermofisher Scientific, MA, USA) and Coffalyser.net software (MRC Holland), following the manufacturer's instructions. The tests were performed at the Human Genetics Laboratory, Ramathibodi Hospital. Carrier status, in the present study, is defined as having only 1 copy of *SMN1* exon 7. The results of carrier testing were reported to the clinician researchers (CT, PP, and MP) within two weeks.

Statistical analyses

Categorical variables were described as the number (percent). Parametric continuous variables were expressed as a mean and standard deviation.

Results

A total of 237 pregnant women were assessed, 35 did not meet the inclusion criteria and four declined to participate, leaving 198 (83.5%) of eligible participants to be enrolled in the

study. Among 181 out of 198 (91.4%) research participants who took the screening test, four were identified as carriers of SMA. Their partners were screened, and none was found to be a carrier, resulting in no couple at risk detected in the present study (Figure 2).

The mean age of the participants was 32 ± 5.1 years and over half (66.2%) of them had a Bachelor's degree or higher (Table 1). None had a child or family relative(s) with SMA. Two-thirds of the participants said that they had never heard of SMA before.

Acceptance and attitudes toward SMA carrier screening

Around 95% or over of the participants agreed that SMA is a serious disorder resulting in severe life suffering, and that the carrier screening could reduce unnecessary anxiety during pregnancy and it should be offered to all pregnant women (Table 2). About 80-92% or more of the participants expressed that having a child with SMA would complicate their life, they were not reluctant to have the screening test done, they had a good faith in the accuracy of the test, and they would have fetal diagnosis if they would be found to be a couple at risk (Table 2). Almost half of the participants expressed their tendency to choose termination of pregnancy for an affected fetus (Table 2).

In the present study, the most common reasons for having the carrier screening included wanting to know their carrier status (87.8%), being worried to have an affected fetus (72.9%), and no extra cost for the test (50.3%) (Table 3). As for those declining the test, they reasoned that SMA was rarely found (58.8%) (Table 3).

Almost half of the participants (47.7%) said that they could afford 501–1,000 Baht (~14-28 USD) if self-pay for the SMA carrier screening. Most participants (95.5%) thought that the

cost of carrier testing should be covered by the government and/or their health coverage schemes (Table 4).

After receiving the result of screening test, all the participants expressed the feeling of glad that they had had the test done. They all agreed that the information about SMA provided to them were very useful and that post-test counseling was essential (Table 5).

SMA carrier rate and frequencies of SMN2 copy number

Only 2.2% (4/181) of the participants were found to be carrier (Table 6). As for the *SMN2*, the majority of participants had 2 copies (58.5%), followed by ≤ 1 copy (39.8%), and ≥ 3 copies (1.7%). Regarding the carrier individuals, three had 2 copies and the other had 1 copy of *SMN2*.

Discussion

We found a high acceptance rate for prenatal SMA carrier testing (91.4%) and positive attitudes towards the screening test, among the pregnant women in this study. Most participants (92%) would choose fetal diagnosis if they were found to be a couple at risk and consider having interruption of pregnancy in case of affected fetus (47%), these finding were in agreement with earlier studies [13, 15]. The majority of the participants suggested SMA carrier testing to be part of standard antenatal care and covered by the public health system.

The low awareness of SMA among the participants, were probably due to the rarity of the disorder; being a hidden problem of SMA owing to the short life of significant proportion of the patients, the patients' low social activities because of respiratory and ambulatory difficulties; and the lack of public health education and screening services for SMA [9, 28, 29].

Despite of generally low awareness of SMA prior to the study, the acceptance rate for SMA prenatal carrier screening was high among the participants in the present study, likely due to several factors including the knowledge about SMA given, perceived usefulness of the preand post-test counseling provided, trust in the test offered, testing at no extra cost (Table 3), and availability of the downstream services. Some studies have shown a significantly increased acceptance rate if covered by medical insurance/health scheme (97.8%) compared to self-funded screening (81.1%) [29, 30]. Other influencing factors included race, parity, and religion [17, 29].

As for those declining the screening test, the main reasons were the low prevalence of SMA (58.8%) and not choosing interruption of the pregnancy for an affected fetus (17.6%). Our findings were consistent with previous reports that people without SMA experience had significantly lower rate of taking carrier testing because they had a dimmer view of the condition than those with experiential knowledge [29, 31]. Therefore, the endorsement from public health authority and professional society and effective mass communications are urgently needed in advancing the SMA carrier screening program [29-31].

The SMA carrier rate found in this study was 1 in 45, with estimated prevalence of SMA at 1 in 8,264, similar to those found worldwide [11, 13, 15, 16, 17-21, 26, 27]. The majority (98.3%) of the participants had \leq 2 copies of *SMN2*, suggesting that a major proportion of Thai affected individuals (fetuses) would be predicted to have the most severe phenotype (type I) of SMA, consistent with other studies [2, 11].

To establish a new prenatal carrier screening program in any country, it is essential to have testing that is acceptable to the target population, with timely turnaround time, appropriate pre-test and post-test counseling, and affordable downstream services including testing for the partners, fetal diagnosis, and choices of continuation and interruption of pregnancy. Other local

context, such as affordable treatment and predicted severity of the disorder, would also tremendously influence the individual's decision on taking or declining the testing. Therefore, population-specific data, both biomedical (carrier rate, copy number of *SMN2*, type of SMA, availability of specific treatment) and sociocultural aspect (religion and extended socioeducational supports) are highly essential for policy planning for each country.

SMA fits all the criteria for prenatal carrier screening, as follows: 1) severity of the disorder; 2) high carrier frequency in the general population more than 1 in 100; 3) available carrier screening test with a high sensitivity and specificity; 4) availability of prenatal diagnosis during early gestation; and 5) timely turnaround time for the screening test and fetal diagnosis [22, 28].

The impact of population-based carrier screening for SMA has been well shown in Israel by that 31% of the cases were prenatally diagnosed following the introduction of the screening through healthcare service and insurance plans (since 2008), and even higher at 52% after it became the national program (since 2013) [30].

To date, Thailand has had a successful prenatal carrier screening program for thalassemia using a sequential testing strategy. Both thalassemia and SMA are inherited in an autosomal recessive fashion. We believe that it is highly pragmatic to incorporate the SMA screening along with thalassemia screening program for Thai population. However, public education of SMA and additional training for healthcare professionals especially those in family medicine and prenatal setting are required. Moreover, the SMA carrier screening can be further expanded to the preconceptional period.

To our knowledge, this study is the first study to evaluate the acceptance of prenatal SMA carrier screening and its influencing factors among Thai population, using a prepared set of educational materials and counseling program. The study is one of a very few studies of its kind, among Asian populations and low-middle income countries which is underrepresented in the literature. The validated Thai-language brochure and the whole process of testing strategy which were approved for its usefulness by the participants could be applied to a large-scale screening among Thai population. Lastly, this is the first demonstration of copy number of *SMN2* among general population of Thais.

The authors appreciated limitations of the study, including a small sample size, the absence of couples at risk and affected fetus identified, which might have resulted in different answers on choosing fetal diagnosis and pregnancy outcome.

Conclusion

The acceptance rate for prenatal SMA carrier screening was high among Thai pregnant women and it could be further amplified by effective mass education to general population and affordable screening services. The estimated prevalence and carrier frequency of SMA among Thai population was found equivalent to the worldwide data and the majority of patients were predicted to have the most severe type of SMA, necessitating the needs for national program for disease prevention. Population-specific data, both biomedical and sociocultural aspects, are markedly important for national policy planning for the carrier screening.

Acknowledgements

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

We are thankful of the Faculty of Medicine Ramathibodi Hospital, Mahidol University for providing Research Career Development Awards to DW, TT, and DD. We thank Melissa Leffler, MBA, from Edanz (www.edanz.com/ac) for editing a draft of this manuscript. **Authors' contributions** Conceptualization: Chayada Tangshewinsirikul, Takol Chareonsirisuthigul, Donniphat Dejsuphong, Duangrurdee Wattanasirichaigoon Data curation: Chayada Tangshewinsirikul, Maneerat Prakobpanich, Takol Chareonsirisuthigul Formal analysis: Chayada Tangshewinsirikul, Takol Chareonsirisuthigul, Duangrurdee Wattanasirichaigoon Funding Acquisition: Chayada Tangshewinsirikul Investigation: Chayada Tangshewinsirikul, Panyu Panburana, Maneerat Prakobpanich, Takol Chareonsirisuthigul, Donniphat Dejsuphong, Thipwimol Tim-aroon, Duangrurdee Wattanasirichaigoon Methodology: Chayada Tangshewinsirikul, Panyu Panburana, Maneerat Prakobpanich, Takol Chareonsirisuthigul, Donniphat Dejsuphong, Thipwimol Tim-aroon, Chaiyos Khongkhatithum, Thanyachai Sura, Atchara Tunteeratum, Duangrurdee Wattanasirichaigoon Supervision: Duangrurdee Wattanasirichaigoon Writing- original draft: Chayada Tangshewinsirikul, Takol Chareonsirisuthigul Writing-review & editing: Duangrurdee Wattanasirichaigoon Data availability statement

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

[Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available

from: https://www.ncbi.nlm.nih.gov/books/NBK1352/

- 351 3. Rashnonejad A, Onay H, Atik T, Atan Sahin O, Gokben S, Tekgul H, et al. Molecular
- Genetic Analysis of Survival Motor Neuron Gene in 460 Turkish Cases with
- Suspicious Spinal Muscular Atrophy Disease. Iran J Child Neurol. 2016;10(4):30-5.
- 4. Verhaart IEC, Robertson A, Leary R, McMacken G, König K, Kirschner J, et al. A
- 355 multi-source approach to determine SMA incidence and research ready population. J
- 356 Neurol. 2017;264(7):1465-73.
- 5. Ogino S, Wilson RB, Gold B. New insights on the evolution of the SMN1 and SMN2
- region: simulation and meta-analysis for allele and haplotype frequency calculations.
- 359 Eur J Hum Genet. 2004;12(12):1015-23.
- 6. Coratti G, Ricci M, Capasso A, D'Amico A, Sansone V, Bruno C, et al. Prevalence of
- 361 Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian
- 362 Nationwide Survey. Neurology. 2023;100(11):522-8.
- 363 7. Lally C, Jones C, Farwell W, Reyna SP, Cook SF, Flanders WD. Indirect estimation
- of the prevalence of spinal muscular atrophy Type I, II, and III in the United States.
- 365 Orphanet J Rare Dis. 2017;12(1):175.
- 366 8. Arikan Y, Berker Karauzum S, Uysal H, Mihci E, Nur B, Duman O, et al. Evaluation
- of exonic copy numbers of SMN1 and SMN2 genes in SMA. Gene.
- 368 2022;823:146322.
- 369 9. Aksaralikitsunti M, Sanmaneechai O. Health-related quality of life in Thai children
- with spinal muscular atrophy. Pediatr Neonatol. 2022;63(3):291-7.
- 371 10. Mailman MD, Heinz JW, Papp AC, Snyder PJ, Sedra MS, Wirth B, et al. Molecular
- analysis of spinal muscular atrophy and modification of the phenotype by SMN2.
- 373 Genet Med. 2002;4(1):20-6.

- Zhao S, Wang W, Wang Y, Han R, Fan C, Ni P, et al. NGS-based spinal muscular
 atrophy carrier screening of 10,585 diverse couples in China: a pan-ethnic study. Eur
 J Hum Genet. 2021;29(1):194-204.
- 377 12. Ogino S, Wilson RB. Genetic testing and risk assessment for spinal muscular atrophy
 378 (SMA). Hum Genet. 2002;111(6):477-500.
- 379 13. Sun Y, Ma S, Xiao J, Wu J, Wu Y, Shi X, et al. Preconception or prenatal acceptance 380 of SMN1 gene carrier screening and carrier rate of spinal muscular atrophy: a 381 retrospective study in 18,818 reproductive age women in Wuhan area of China. J 382 Assist Reprod Genet. 2024;41(1):127-33.
- Tan J, Zhang J, Sun R, Jiang Z, Wang Y, Ma D, et al. Evaluating the performance of
 four assays for carrier screening of spinal muscular atrophy. Clin Chim Acta.
 2023;548:117496.
 - Huang Z, Yang Q, Ye J, Huang J, Lin J, Chen J, et al. Screening and prenatal diagnosis of survival motor neuron gene deletion in pregnant women in Zhaoqing city, Guangdong Province. BMC Med Genomics. 2023;16(1):39.

387

388

- 389 16. Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM, et al. Pan-ethnic 390 carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical 391 laboratory analysis of >72,400 specimens. Eur J Hum Genet. 2012;20(1):27-32.
- Wood SL, Brewer F, Ellison R, Biggio JR, Edwards RK. Prenatal Carrier Screening
 for Spinal Muscular Atrophy. Am J Perinatol. 2016;33(12):1211-7.
- Feldkötter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of
 SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier

396 testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 397 2002;70(2):358-68. 19. 398 Cusin V, Clermont O, Gérard B, Chantereau D, Elion J. Prevalence of SMN1 deletion 399 and duplication in carrier and normal populations: implication for genetic 400 counselling. J Med Genet. 2003;40(4):e39. 401 20. Hendrickson BC, Donohoe C, Akmaev VR, Sugarman EA, Labrousse P, 402 Boguslavskiy L, et al. Differences in SMN1 allele frequencies among ethnic groups 403 within North America. J Med Genet. 2009;46(9):641-4. 404 21. Smith M, Calabro V, Chong B, Gardiner N, Cowie S, du Sart D. Population screening 405 and cascade testing for carriers of SMA. Eur J Hum Genet. 2007;15(7):759-66. 406 22. Prior TW. Carrier screening for spinal muscular atrophy. Genet Med. 407 2008;10(11):840-2. 408 23. Committee Opinion No. 691: Carrier Screening for Genetic Conditions. Obstet 409 Gynecol. 2017;129(3):e41-e55. 410 24. Wanapirak C, Tongsong T, Sirivatanapa P, Sa-nguansermsri T, Sekararithi R, 411 Tuggapichitti A. Prenatal strategies for reducing severe thalassemia in pregnancy. Int 412 J Gynaecol Obstet. 1998;60(3):239-44. 413 25. Paiboonsukwong K, Jopang Y, Winichagoon P, Fucharoen S. Thalassemia in 414 Thailand. Hemoglobin. 2022;46(1):53-7. 415 26. Dejsuphong D, Taweewongsounton A, Khemthong P, Chitphuk S, Stitchantrakul W,

Sritara P, et al. Carrier frequency of spinal muscular atrophy in Thailand. Neurol Sci.

416


417

2019;40(8):1729-32.

27. Chaisomchit S. Thongnoppakhun W. Pho-iam T. Limwongse C. Likasitwattanakul S. 418 Chareonsiriwatana W, et al. Investigation of carrier frequency for spinal muscular 419 420 atrophy in Thailand using dried blood spot specimens. Genomics and Genetics. 421 2016;9(2&3): 78-84. 422 28. Prior TW, Snyder PJ, Rink BD, Pearl DK, Pyatt RE, Mihal DC, et al. Newborn and 423 carrier screening for spinal muscular atrophy. Am J Med Genet A. 424 2010;152a(7):1608-16. 425 29. Li Y, Wang L, Tan J, Huang M, Wang Y, Shao B, et al. Current attitudes toward 426 carrier screening for spinal muscular atrophy among pregnant women in Eastern 427 China. J Genet Couns. 2023;32(4):823-32. 428 30. Aharoni S, Nevo Y, Orenstein N, Basel-Salmon L, Ben-Shachar S, Mussaffi H, et al. Impact of a national population-based carrier-screening program on spinal muscular 429 430 atrophy births. Neuromuscul Disord. 2020;30(12):970-4. Boardman FK, Young PJ, Warren O, Griffiths FE. The role of experiential knowledge 431 31. 432 within attitudes towards genetic carrier screening: A comparison of people with and 433 without experience of spinal muscular atrophy. Health Expect. 2018;21(1):201-11. 434

435

Sequential prenatal SMA carrier screening protocol






Figure 2 Prenatal carrier screening among 198 pregnant women